2 days Ago By Defense World Staff
American Century Companies Inc. trimmed its holdings in shares of Ascendis Pharma A/S ( NASDAQ:ASND – Free Report ) by 0.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission.
The firm owned 305,974 shares of the biotechnology company’s stock after selling 167 shares during the quarter. American Century Companies Inc. owned approximately 0.
53% of Ascendis Pharma A/S worth $41,729,000 as of its most recent SEC filing. A number of other large investors also recently bought and sold shares of the business. Headlands Technologies LLC bought a new position in shares of Ascendis Pharma A/S in the 2nd quarter worth $864,000.
Candriam S.C.A.
grew its stake in Ascendis Pharma A/S by 96.6% in the second quarter. Candriam S.
C.A. now owns 195,347 shares of the biotechnology company’s stock valued at $26,640,000 after purchasing an additional 95,972 shares during the last quarter.
Rhumbline Advisers raised its holdings in Ascendis Pharma A/S by 10.3% in the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 143 shares in the last quarter.
Searle & CO. purchased a new stake in shares of Ascendis Pharma A/S during the second quarter valued at about $205,000. Finally, Legato Capital Management LLC boosted its holdings in shares of Ascendis Pharma A/S by 167.
6% in the 2nd quarter. Legato Capital Management LLC now owns 4,324 shares of the biotechnology company’s stock valued at $590,000 after buying an additional 2,708 shares in the last quarter. Ascendis Pharma A/S Trading Up 17.
1 % ASND opened at $139.57 on Tuesday. The firm has a 50 day moving average of $132.
51 and a two-hundred day moving average of $136.47. The firm has a market capitalization of $8.
13 billion, a PE ratio of -14.52 and a beta of 0.63.
Ascendis Pharma A/S has a 12-month low of $85.29 and a 12-month high of $161.00.
Analyst Ratings Changes Check Out Our Latest Stock Report on Ascendis Pharma A/S About Ascendis Pharma A/S ( Free Report ) Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Further Reading Five stocks we like better than Ascendis Pharma A/S What are earnings reports? Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible Uptrend Stocks Explained: Learn How to Trade Using Uptrends Roblox’s Growth Beyond Kids: Stock Set for Major Moves The 3 Best Fintech Stocks to Buy Now 5 Oversold Stocks to Buy Right Now Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter ..
